A retrospective observational study of adverse events following COVID-19 vaccination in South Korea
Latest Information Update: 13 May 2022
Price :
$35 *
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 13 May 2022 New trial record
- 01 May 2022 Results published in the International Journal of Infectious Diseases